04:00 PM EST - Theratechnologies : said it now expects to have an official response from the U.S. Food and Drug Administration regarding the timeline to review tesamorelin's new drug application in the fourth quarter of 2010. Earlier, the FDA had set July 27 as action date for tesamorelin. Tesamorelin, whose brand name is Egrifta, is an analogue of the human growth hormone releasing factor. The company is seeking FDA approval for Egrifta for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies
shares T.TH are trading down $0.59 at $4.89.
